All News

    Breaking Down the CheckMate 901 Trial Data for Metastatic Bladder Cancer

    June 2nd 2025, 2:00pm

    Article

    Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma.

    Imfinzi Combo Boosts Survival in Resectable Gastric and GEJ Cancer

    June 2nd 2025, 1:46pm

    Article

    Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and gastroesophageal junction cancer.

    Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer

    June 1st 2025, 12:00pm

    Article

    Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.

    Camizestrant and CDK4/6 Inhibition Benefits Outcomes in Breast Cancer Subgroups

    June 1st 2025, 12:00pm

    Article

    Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer.

    Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer

    June 1st 2025, 12:00pm

    Article

    Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.

    Trodelvy/Keytruda Extends PFS Versus Chemo/Keytruda in PD -L1+ TNBC

    May 31st 2025, 12:10pm

    Article

    Trodelvy plus Keytruda, when given in the frontline, extended survival without progression versus chemo plus Keytruda in PD-L1+ metastatic TNBC.

    Enhertu Improves Survival End Points Vs Cyramza/Paclitaxel in HER2+ GC/GEJ

    May 31st 2025, 12:05pm

    Article

    Second-line Enhertu improved key survival end points versus Cyramza plus paclitaxel for HER2+ gastric cancer or gastroesophageal junction adenocarcinoma.

    Vepdegestrant Boosts Outcomes in ESR1-Mutant ER+/HER2– Advanced Breast Cancer

    May 31st 2025, 12:00pm

    Article

    Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when compared with Faslodex.

    Rapid Developments to Enhance Patient Experience in GU Cancer

    May 30th 2025, 9:00pm

    Article

    New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while personalizing patient outcomes.

    Additive Antihistamines May Improve Metastatic Bladder Cancer Outcomes

    May 30th 2025, 7:00pm

    Article

    Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq.